The estimated Net Worth of Thomas J. Farrell is at least $134 Tisíc dollars as of 1 October 2015. Thomas Farrell owns over 2,500 units of Bellicum Pharmaceuticals Inc stock worth over $4,774 and over the last 10 years Thomas sold BLCM stock worth over $129,000.
Thomas has made over 3 trades of the Bellicum Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Thomas sold 2,500 units of BLCM stock worth $36,450 on 1 October 2015.
The largest trade Thomas's ever made was selling 2,500 units of Bellicum Pharmaceuticals Inc stock on 1 October 2015 worth over $36,450. On average, Thomas trades about 1,071 units every 8 days since 2014. As of 1 October 2015 Thomas still owns at least 63,862 units of Bellicum Pharmaceuticals Inc stock.
You can see the complete history of Thomas Farrell stock trades at the bottom of the page.
Thomas's mailing address filed with the SEC is C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON, TX, 77030.
Over the last 10 years, insiders at Bellicum Pharmaceuticals Inc have traded over $18,000,835 worth of Bellicum Pharmaceuticals Inc stock and bought 249,666 units worth $2,145,232 . The most active insiders traders include Bros. Advisors Lp Baker Bro..., Bros. Advisors Lpbaker Feli... a Jon P Stonehouse. On average, Bellicum Pharmaceuticals Inc executives and independent directors trade stock every 32 days with the average trade being worth of $2,494. The most recent stock trade was executed by James M Daly on 3 January 2023, trading 60,414 units of BLCM stock currently worth $4,516.
bellicum pharmaceuticals, located near the houston medical center, is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. we are developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (hsct) and car t cell therapy. we are dedicated to creating an exceptional work environment and are passionate about working to provide innovative new treatment options that can improve health and save lives.
Bellicum Pharmaceuticals Inc executives and other stock owners filed with the SEC include: